Supplementary Note 1
We investigated the profiling of colorectal cancer specific autoantibodies on a modified version of ProtoArrays with different surface properties; we probed 20 sera from CRC and control patients ( Supplementary Fig. S1a and Supplementary Table S1 ). After performing a high-stringent bioinformatic analysis we selected only those proteins that were coincident in three bioinformatic analyses and showed the highest prevalence in CRC patients. By using the Prospector Analyzer tool, we identified 24 proteins showing immunoreactivity with cancer sera, having a p value<0.04 and a prevalence >50% in the CRC group (Supplementary Table S2 ). In addition, normalized data were processed using T-Rex from the GEPAS web-tool database and Pomelo II. From 24 initiallyidentified candidates, we found 5 CRC-associated antigens coincident in all three analyses ( Supplementary Fig. S1b ). From these five, we selected three antigens (EDIL3, GTF2B and HCK) that showed prevalence >60% in the CRC group and <20% in the control group ( Supplementary Fig. S1b ).
Although, we have not found any association of these proteins to colorectal carcinoma, EDIL3, GTF2B and HCK might play an important role in colon tumorigenesis and as CRC diagnostic markers since they have been reported to develop important cellular functions. Indeed, EDIL3 binds αvβ3 integrin and plays a role in angiogenesis and vascular morphogenesis 1 . High expression of EDIL3 has been associated to poor prognosis in hepatocellular carcinoma 2 . GTF2B, general transcription factor IIB, is required for transcription initiation by RNA polymerase II. It plays a major role in the activation of eukaryotic genes transcribed by RNA polymerase II 3 . HCK (hematopoietic cell kinase) belongs to the Src family of tyrosine kinases and has been reported to be involved in phagocytosis, adhesion and migration, to regulate formation of membrane protrusions, lysosome exocytosis, podosome formation, actin polymerization, and has been associated to cancer 4, 5, 6 . Then, to confirm the suitability of these new identified TAAs as potential CRC diagnostic markers, we used them, in combination with p53, for the screening of an independent set of 153 serum samples (50 CRC, 49 healthy samples, and 54 sera from other related diseases) (Supplementary Table S1 ). Although all the CRC TAAs were able to discriminate between CRC and control samples, best differential values were obtained for GTF2B and HCK, with p values <0.01 ( Supplementary Fig. S1c ). In both cases, the comparison of healthy samples versus other related cancers did not give significant values. However, p53 reactivity was similar for CRC and samples from other cancers, indicating a low specificity of p53 antibodies for colon cancer. No reactivity was observed against control Annexin IV ( Supplementary Fig. S1c ). To determine specificity and sensitivity, receiver operating characteristics (ROC) curves were generated for each of these TAAs to discriminate CRC. The areas under the curve (AUC) values were relatively low for individual antigens, ranging between 0.58 to 0.67 for EDIL3, GTF2B and HCK and 0.62 for p53. However, the combination of markers gave an AUC of 0.75 ( Supplementary Fig. S1d and Supplementary Fig. S2 ).
Collectively, these data support the capacity of EDIL3, GTF2B and HCK TAAs as candidate biomarkers for the diagnosis of CRC. Therefore, we incorporated these TAAs in subsequent studies for autoantibody responses in murine models of sporadic colon cancer. Table S1 ). A representative microarray incubated with sera from a CRC patient is shown, together with a highlighted sub-array to observe the presence of reactive proteins i d b t tib di t i th f CRC ti t C t l t l t d i b th f h b I d recognized by autoantibodies present in the sera of CRC patients. Control spots were located in both corners of each subarray. In red, proteins reacting with CRC serum. In white, saturated control spots. (b) The five TAAs identified with all three bioinformatic approaches: i) Pomelo II, ii) T-Rex, and iii) ProtoArray Prospector Analyzer. Prevalence values correspond to that obtained from the Prospector Analyzer. Ratio was calculated with the fluorescence intensity for each TAA from the median of CRC and Control group. Database ID, accession number of the TAA (c) ELISA with serum samples from CRC patients healthy individuals (H) and related diseases patients (RD) was number of the TAA. (c) ELISA with serum samples from CRC patients, healthy individuals (H) and related diseases patients (RD) was performed using human recombinant EDIL3, GTF2B, HCK, and p53. Annexin IV was used as negative control (Supplementary Table S1 ). microarrays were washed again with PBST five times for 5 min, rinsed with deionized water and dried by centrifugation at 1000 rpm for 1 min. Microarray data were acquired using a ScanArray ™ 5000 MicroArray scanner (Packard BioChip Technologies). The arrays were scanned using 635 nm and 532 nm lasers and a resolution of 10 μm / pixel to produce red (Alexa Fluor 647) or green images (Alexa Fluor 555). Finally, the Genepix Pro 7 (Molecular Devices) image analysis software was used for quantification.
Name
Statistical Analysis. Microarrays were analyzed by three approaches to identify tumor associated antigens differentially recognized by the sera of CRC patients' sera and reference controls' sera: i) paired t tests using Pomelo II (http://pomelo2.bioinfo.cnio.es/) considering two classes (CRC and control) 10 , ii) T-Rex tool for analyzing differential expression between two conditions (CRC and control) after preprocessing for normalization of data, which is included in the web-based tool GEPAS 4.0 (http://www.gepas.org/) 11 , and iii) the array manufacturer's software ProtoArray Prospector Analyzer 4.0 (Invitrogen), which relies on Chebyshev's inequality principle 7 , which determines if a fluorescent signal on the microarray is significant using the negative controls printed in the array. We select as colorectal cancer-specific antigens those proteins that appeared in all three bioinformatics analysis ( Supplementary Fig.   S1b ).
